



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/29

May 25, 2023

To, The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Manager National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	Scrip Symbol – Biocon

Subject: Newspaper Advertisement- Financial Results for the Quarter and Financial Year ended March 31, 2023

Dear Sir/Madam,

In continuation to our letter dated May 23, 2023 with regards to Financial Results for the quarter and year ended March 31, 2023, please find enclosed copies of newspaper advertisement published in Financial Express (English Language-All India Edition) and Vijayavani (Kannada-Bengaluru Edition) on May 25, 2023.

The above information is also available on the website of the Company at www.biocon.com.

Kindly take the above information on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**


Mayank Verma
Company Secretary & Compliance Officer
Membership No.: ACS 18776

Enclosed: Copies of Newspaper advertisements



Registered Office:
Biocon Limited
20th KM Hosur Road,
Electronic City P.O.,
Bangalore - 560 100

www.biocon.com
CIN: L24234KA1978PLC003417



EXTRACT OF AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2023

(Rs. in Million, except per equity share data)

Particulars	3 months ended 31.12.2023	Year ended 31.03.2023	Year ended 31.03.2022
	Audited	Audited	Audited
I Revenue from operations	37,739	1,11,742	81,840
II Profit before exceptional items and tax	4,996	11,885	10,942
III Profit before tax	4,966	8,971	9,831
IV Profit attributable to shareholders of the Company	3,132	4,627	6,484
V Total comprehensive income attributable to shareholders of the Company	2,503	5,765	7,451
VI Paid-up equity share capital [Face value of Rs. 5 each]	6,003	6,003	6,003
VII Reserve [Excluding Revaluation Reserve] as shown in the audited balance sheet		1,72,657	78,313
VIII Earnings per share [of Rs. 5 each]	(not annualised)	(annualised)	(annualised)
(a) Basic	2.62	3.88	5.44
(b) Diluted	2.62	3.87	5.42

1. Key standalone financial information

Particulars	3 months ended 31.12.2023	Year ended 31.03.2023	Year ended 31.03.2022
	Audited	Audited	Audited
I Revenue from operations	5,067	19,929	17,382
II Profit before tax	17,961	29,712	1,397
II Net Profit for the period	18,108	28,484	861

- The audited standalone and consolidated financial results for the quarter and year ended **March 31, 2023** in respect of Biocon Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on **May 23, 2023**. The reports of the statutory auditors are unqualified.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above is an extract of the detailed format of audited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the audited Financial Results are available on the Stock Exchange websites, www.nseindia.com and www.bseindia.com and on the Company's website www.biocon.com.